The expression of the transglutaminase 2 (TGM2) gene is generally associated with poor prognosis in pancreatic cancer and is involved in its initiation, inflammation, and progression, making it a target marker in studies analyzing drugs with chemosensitizing activity [80,81,82]. The gene discussed is TGM2; the disease is familial pancreatic carcinoma.